Senator Leahy Urges NIH to Use March-In Rights on Myriad BRCA Test
By Donald Zuhn,
Patent Docs
| 07. 17. 2013
On Friday, Sen. Patrick Leahy (D-VT) sent a
letter to Dr. Francis Collins, the Director of the National Institutes of Health (NIH), "to urge [the Director] to consider using march-in rights under the Bayh-Dole Act to ensure greater access to genetic testing for breast and ovarian cancer." The Bayh-Dole Act, which was enacted in 1980, created a uniform patent policy among the many federal agencies that fund research, enabling small business and non-profit organizations -- including universities -- to retain title to inventions made under federally funded research programs. In commemorating the Act's 30th anniversary in 2010, the U.S. Patent and Trademark Office noted that "[t]he legislation is credited with the creation of thousands of new companies and billions of dollars of direct benefits to the U.S. economy" (see "
USPTO Recognizes 30th Anniversary of Bayh-Dole Act").
As a result of the concern that U.S. taxpayers should not have to pay businesses for inventions that the public has already paid for, legislators added a section to the Act that gave the government "march-in" rights. Recently, a handful of groups...
Related Articles
By Ed Cara, Gizmodo | 06.22.2025
In late May, several scientific organizations, including the International Society for Cell and Gene Therapy (ISCT), banded together to call for a 10-year moratorium on using CRISPR and related technologies to pursue human heritable germline editing. The declaration also outlined...
By Julia Métraux, Mother Jones | 05.28.2025
By Darren Incorvaia, Fierce Biotech | 06.05.2025
By Matthew Purdy, The New York Times | 05.29.2025
Image “Elon Musk” by Debbie Rowe, Royal Society on
Wikimedia Commons licensed under CC by S.A. 3.0
As Elon Musk prepared to make a less than triumphant exit from Washington, he told the Fox News host Jesse Watters earlier this...